Mechanistic Insights of Meglitinides Drug Repurposing and Delivery to Brain for Metabolic Syndrome Linked Neurodegenerative Disease

Abstract

Metabolic syndrome (MS) includes clusters of metabolic disorders and type 2 DM (T2DM) is most common MS which cause insulin resistance (IR). The IR mediated dysregulation of signaling cascades in brain increase the production and secretion of Aβ, p-tau which prompt to Alzheimer’s (AD). Therefore, repaglinide (REP) a meglitinides drug is used, which act by targeting ATP binding cassette and evidence indicated that REP increase neuronal survival via upregulating ATF-6 gene and blocking the DREAM. Thus, there is huge possibility that REP regulate and modulate the expression of pro-apoptotic protein, anti-apoptotic protein, calcium homeostasis and may eventually reduce the neuronal cell death.